The approval is based on findings from the phase 3, multicenter, open-label, randomized TROPION-Breast01 trial.

As supported by data from the phase 3 TROPION-Breast01 trial, datopotamab deruxtecan is now an FDA-approved treatment for ...

DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.

Overall survival, defined as the time from randomization ... status on their preneoadjuvant therapy biopsy specimen and HER2-negative status on their postneoadjuvant therapy residual disease ...

During a Case-Based Roundtable event, Laura Huppert, MD, reviewed antibody-drug conjugates for a patient with metastatic ...

Approval is based on results from the TROPION-Breast01 Phase III trial, in which Datroway demonstrated a significant reduction in the risk of disease progression or death in patients with previously ...

Datroway has been approved for unresectable or metastatic HR+, HER2- breast cancer after endocrine therapy and chemotherapy.

An updated long-term analysis of the Phase III KATHERINE trial confirms that adjuvant treatment with Kadcyla (trastuzumab ...

Adjuvant ado-trastuzumab emtansine significantly prolonged survival compared with trastuzumab for certain women with ...

The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with ...

DXd, has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor HR-positive, HER2-negative breast cancer who have received prior endocrine-based ...